Really interesting that you mention this. I had the same exact thought when I read about the failure of Abbott's kidney program. The also have a Parkinson's candidate in Phase 3 so all of the sudden the tardive dyskinesia program looks like an interesting fit for Abbott. I've always felt that NBIX should be bought by Abbott. The pipeline isn't as robust as it used to be, but elagolix has such huge potential. Abbott needs to build their story as you said. It's really important for them.
I remember emailing Dr. O'Brien over a year ago and asked him if VMAT2 might be applicable to Parkinson's. My thinking was apparently like yours in that both tardive and Parkinson's are characterized by involuntary movements. His answer was no, but I can't remember why. Perhaps something about different receptors. If Abbott does go after NBIX, let's hope we start the bidding at a higher level than seven or eight bucks. I don't see them offering a 100% premium.